The Effects of Thrombocytopenia at Diagnosis of MDS

A recent abstract from the 2025 American Society of Hematology (ASH) meeting examined the prognostic impact of thrombocytopenia at diagnosis in Myelodysplastic Syndromes (MDS). The findings align with growing evidence that low platelet counts at diagnosis, or an early subsequent drop, are associated with worse clinical outcomes. For instance, studies show patients with low platelet counts decline in the first 6 months have significantly inferior overall survival and higher risk of progression to acute myeloid leukemia.